Show simple item record

dc.contributor.authorGoyal, V
dc.contributor.authorMarchant, J
dc.contributor.authorGrimwood, K
dc.contributor.authorMasters, B
dc.contributor.authorYerkovich, S
dc.contributor.authorChang, A
dc.date.accessioned2021-05-24T03:47:28Z
dc.date.available2021-05-24T03:47:28Z
dc.date.issued2021
dc.identifier.issn1323-7799
dc.identifier.urihttp://hdl.handle.net/10072/404616
dc.description.abstractIntroduction/Aim: Respiratory exacerbations in children with bronchiectasis are treated with antibiotics. While oral antibiotics are superior to placebo and recommended by guidelines to treat children with non-severe (non-hospitalized) exacerbations, not all will benefit. Therefore, we aimed to identify factors predicting those who will improve after a 14-day oral antibiotic course. Methods: Demographic and clinical data from our two recently completed double-blind, double-dummy, randomized controlled trials were retrieved for the 202 children who received at least 14-days of oral antibiotics to treat their non-severe exacerbations. Univariable and multivariable logistic regression was used to identify factors associated with their response to antibiotics. Results: Of the 202 children (51% males), 41% were Indigenous (Maori or Australian First Nations). Their median age was 4.2 (interquartile range 2.3–6.7) years at diagnosis of bronchiectasis. All received 14-days of amoxicillin-clavulanate or azithromycin. By Day-14, 130 (64%) children had improved according to validated cough score and clinical assessments, while 72 had not. Baseline characteristics were similar in both responder and non-responder groups. Univariable analysis found significant differences between groups for Indigenous ethnicity, number of non-hospitalized exacerbations needing antibiotics in the preceding 2-years, and number of lobes affected by bronchiectasis. Following multivariable analysis, Indigenous ethnicity (ORadjusted=4.70 95%CI 2.20–10.01), cough score at the exacerbation beginning (ORadjusted=0.58 95%CI 0.39–0.86) and number of lobes affected by bronchiectasis (ORadjusted=0.75 95%CI 0.57–0.99) were significant factors in identifying responders. Detecting a respiratory virus at the beginning of an exacerbation did not affect the response to antibiotics. Conclusion: Among children with a non-severe bronchiectasis exacerbation, those more likely to respond to oral antibiotics were of Indigenous background, had less severe bronchiectasis as judged by a fewer number of affected lobes, and had less severe cough scores at the beginning of an exacerbation than those lacking these factors.
dc.languageEnglish
dc.publisherWILEY
dc.publisher.urihttps://onlinelibrary.wiley.com/doi/10.1111/resp.14021
dc.relation.ispartofconferencenameTSANZSRS 2021
dc.relation.ispartofconferencetitleRespirology
dc.relation.ispartofdatefrom2021-05-01
dc.relation.ispartofdateto2021-05-02
dc.relation.ispartoflocationVirtual
dc.relation.ispartofpagefrom79
dc.relation.ispartofpageto79
dc.relation.ispartofissueS2
dc.relation.ispartofvolume26
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchcode32
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRespiratory System
dc.titleBronchiectasis exacerbations in children: What predicts the response to antibiotics?
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationGoyal, V; Marchant, J; Grimwood, K; Masters, B; Yerkovich, S; Chang, A, Bronchiectasis exacerbations in children: What predicts the response to antibiotics?, Respirology, 2021, 26, pp. 79-79
dc.date.updated2021-05-21T06:49:18Z
gro.hasfulltextNo Full Text
gro.griffith.authorGrimwood, Keith


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record